Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired clonal hematopoietic stem cell disease that manifests as hemolytic anemia, bone marrow failure, smooth muscle dystonia and thrombosis [1] [2] [3] [4] [5] . PNH originates from a multipotent hematopoietic stem cell that acquires a mutation in a gene called phosphatidylinositol glycan anchor biosynthesis, class A (PIG-A) located on chromosome Xp22.1. This leads to partial or absolute deficiency of all 'glycophosphatidyl-inositol-anchor proteins' (GPI-AP) [6, 7] . These proteins serve different functions like enzymes, receptors; complement regulators and adhesion molecules [8] . The protein deficiencies such as CD55 (decay accelerating factor, DAF) and CD59 (membrane inhibitor of reactive lysis, MIRL) leads to complement mediated cell lysis and other clinical manifestations [1] .
Various tests like modified Ham's test, sucrose lysis test, gel card technique (GCT) and flow cytometry-based testing are available for making diagnosis [9] [10] [11] [12] . Recently, in multicolour flow cytometry, bacterial aerolysin tagged with fluorescent antibody (FLAER) was used which binds specifically to the GPI moiety of cell surface GPI-linked molecules and causes lysis of normal but not GPI-deficient PNH cells [13] [14] [15] [16] . This review aims at giving brief overview of clinical manifestations of PNH and its pathogenesis, different diagnostic tests available for detection of PNH clone, and its recent advances in recommendations for making its diagnosis.
Clinical Manifestations of PNH and Its Pathogenesis The Role of Complement in Intravascular Hemolysis
Most important among the 'GPI-APs' are CD55 (DAF) and CD59 (MIRL) which play a vital role in the regulation of complement activation by preventing it from being attached to cell membranes [1] [2] [3] [4] [5] . The absence of CD59 from the surface of PNH erythrocytes leads to intravascular hemolysis and hemoglobinuria which manifest as colacolored urine and subsequently, iron deficiency anemia. There are three pathways by which complement is activated, namely classical, lectin and alternative pathway [5] . Hemolysis in PNH is chronic due to a continuous state of alternate complement pathway activation, but paroxysms may result from increase in complement activation due to infection, surgery, strenuous activity, and excessive alcohol intake [1] [2] [3] [4] [5] . Since there are no antibodies involved in this process of hemolysis, PNH should be suspected in all cases of Coombs-negative hemolytic anemia. Usually fatigability is out of proportion to the degree of anemia due to cytokines involved in this process [17] . Depending on the complement sensitivity to lysis, these PNH cells are categorised into type I (normal sensitivity), type II (3-5 times more sensitive) and type III cells (15-25 times more sensitive to lysis) [18] .
Nitric Oxide Scavenging in PNH
Nitric oxide plays an important role in maintaining the vascular tone and limiting platelet activation. Intravascular hemolysis in PNH causes free hemoglobin release into plasma which scavenges nitric oxide resulting in various manifestations like fatigue, abdominal pain, dysphagia, male erectile dysfunction and possibly thrombosis [1] [2] [3] [4] [5] .
Bone Marrow Failure Syndromes
Approximately 30-45% of PNH patients have some kind of bone marrow failure syndromes such as aplastic anemia (AA), myelodysplastic syndrome (MDS); typically refractory anemia and unexplained cytopenia(s) [19] . Mahapatra et al. [20] in their extensive study of 1501 AA patients, PNH clone was detected in 39.7% at diagnosis. Similarly various studies report that at least 40-70% of AA patients have detectable level of PNH clone [21] [22] [23] [24] [25] [26] [27] .
Two-hit hypothesis model has been proposed to explain the clonal expansion in PNH. The first hit involves the benign event such as PIG-A mutation occurring in hematopoietic stem cells and the second hit involves the immune selection that selectively destroys the normal stem cells sparing the PNH stem cells. This plays a major role in clonal selection and expansion of the PNH clones [6, 7] . This also explains the possible association of acquired AA with autoimmune basis of the disease and PNH [28] [29] [30] .
Thrombosis in PNH
Thrombosis is the leading cause of mortality and significant morbidity in PNH patients. It occurs mostly in venous system in 30-40% of patients. The PNH clone size of [50% in granulocytes correlates highly with thrombotic risk. The exact mechanism of thrombosis is not entirely understood, however various postulation have been put forward to explain the association. Nitric oxide depletion, lack of 'GPI-AP' such as urokinase receptor and tissue factor pathway inhibitor (TFPI) cause defective fibrinolysis and loss of inhibition of tissue factor [18, [28] [29] [30] .
Any unexplained thrombosis such as stroke, myocardial infarction, pulmonary emboli and deep vein thrombosis or unusual sites such as hepatic vein thrombosis manifesting as Budd-Chiari syndrome, other intra-abdominal veins such as portal or mesenteric vein thrombosis, cerebral sinus thrombosis, dermal vein thrombosis or thrombosis associated with hemolysis or unexplained cytopenia(s) should be investigated for PNH [31] . Also, a higher failure rate is noted with anticoagulant therapy in a subset of patients with PNH [32] .
Classification of PNH
The International PNH interest group (IPIG) established the classification system bringing the clinicians and the researchers together for the diagnosis and quantification of PNH clones. Three subgroups were proposed as follows: (1) Classical PNH is characterised by the clinical evidence of intravascular hemolysis, presence of large granulocyte clone and the majority of the RBCs are of type III (complete 'GPI-AP' deficiency) PNH cells; (2) PNH arising in the setting of other bone marrow disorders such as AA and MDS; (3) Subclinical PNH (PNH-sc), highly sensitive flow cytometer assay is required to diagnose this entity because of the presence of smaller clone size along with other bone marrow disorders. Overt symptoms of PNH are not present [3] .
Detection of PNH Clones
Various modalities are currently being used to diagnose PNH. In the following sections, we will see about their basic principle, advantages and disadvantages.
Complement Based Test
Modified Ham's test and sucrose lysis test, both are traditional tests, based on the principle that PNH red cells are sensitive to undergo activated complement protein mediated cell lysis. The detection limit of these tests is between 4.2 and 5% [9] . These tests are inexpensive, but require a dedicated technician, laborious and not suitable for routine testing. It is not accurately quantitative, might not give valuable results during hemolytic episodes and following blood transfusion. Moreover, it is not specific, gives false positive results in congenital dyserythropoietic anemia type II, few cases of megaloblastic anemia and autoimmune hemolytic anemia [12, 33] .
Gel Card Technique (GCT)
This test is based on antigen-antibody reaction. The advantage is its sensitivity ranges between 2 and 10%, is comparable with complement based test and also simple, inexpensive and easy to interpret [9, 33] . But the major disadvantage is that it is not quantitative, not sensitive to pick up smaller clones, not able to detect PNH cells in a patient who had received blood transfusion in the recent past and during hemolytic episodes [10, 12] .
Flow Cytometry Based Test
This utilises monoclonal antibodies tagged with fluorochromes which bind specifically to 'GPI-AP' on peripheral blood cells or FLAER which binds directly to GPI anchor itself [9, 11] . It is rapid, sensitive; gives better assessment of clone size and delineation of type I, II and III cells. This has now become the 'gold standard' test for diagnosis of PNH [12, [33] [34] [35] . However, detailed knowledge of various monoclonal antibodies commercially available, their pattern of expression on cells at various stages of maturation, appropriate panel of antibodies to be used and proper gating strategy is required [36, 37] .
Pre-analytical Variables Which is Ideal Sample? Peripheral Blood or Bone Marrow for Analysis
The recent ICCS guidelines recommend the use of peripheral blood for PNH testing. Bone marrow samples should not be used for routine clinical laboratory testing; this is because immature myeloid cells often lack uniform expression of 'GPI-AP' [31] . Also in MDS, often there is altered expression of CD16 on granulocytes and difficult to interpret test results in the presence of smaller PNH clone [14, 21, 31] .
Specimen Collection and Handling
Ideally venous blood should be collected into vacutainer tube containing anticoagulant such as ethylenediamine tetra-acetic acid (EDTA); heparin or acid citrate dextrose (ACD) is also acceptable. The test should be performed within 48 h of sample collection. However if there is delay in testing, samples should be stored at 4°C for maximum of 1 week. Type III red cells might undergo hemolysis in vitro beyond this period [31] .
Analysis of RBC
In PNH, hemolysis is one of the major manifestations of the disease. So analysis of RBC for the expression of various 'GPI-AP' was carried out from the initial experimental studies [34, 35] . It is stressed that while doing sample preparation, particularly for RBC, it is better to avoid excess of protein support during both the incubation and washing step as this causes agglutination of RBC [31] . Similarly in selecting the fluorochromes, phycoerythrin (PE) is recommended when compared to fluorescent isothiocyanate (FITC), as the latter causes agglutination and less distinction between type I, II and III cells [31, 37] .
The GPI-linked markers such as CD55 and CD59 are commonly used for analysis of RBC. Simultaneous use of both these markers are advised, because a very rare hereditary disorder in which absence of individual markers CD55 ('Inab' phenotype) and CD59 have been reported [34] . The intensity of CD59 expression is stronger than CD55 and therefore recent guidelines give more weightage for CD59 [31] . Routinely, the gating strategy for RBC is based on light scatter properties such as forward scatter and side scatter (FSC and SSC) in log mode. In order to increase the sensitivity, it is now recommended to use glycophorin A (CD235-FITC). However, care must be taken to ensure adequate washing step to avoid agglutination of RBC when using this marker [36, 37] .
Phenotypic mosaicism is the hallmark of the disease as this is manifested as marked variation in the distinction of type I, II and III cells. Therefore, testing of RBCs alone is not recommended because of reduced clone size by hemolysis and recent blood transfusion [31, 38, 39] . In the presence of hemolysis, few authors studied the clone size of reticulocytes stained with CD59 and thiazole orange and found to correlate well with clone size of granulocytes. However, this has no clinical utility and hence not recommended [40, 41] . The advantage with analysis of RBC by flow cytometry is that even after blood transfusion, PNH clone could be picked up however it would underestimate the clone size, because transfused RBCs show normal expression of CD55 and CD59 [31, 38, 39] .
Analysis of WBC
There are three technical protocols available for WBC sample preparation. They are (1) lyse-wash-stain technique, (2) stain-lyse-wash technique and (3) stain-no lyse-no wash technique [36] . In our experience, the first technique which includes initial lysis of RBC by ammonium chloride based reagent, washing with phosphate buffered saline (PBS) followed by staining with monoclonal antibodies gives better result and also recommended by ICCS. This seems to be more economical as it prevents non-specific binding and lesser quantities of monoclonal antibodies used [31] .
In cases of AA and MDS, another technical issue to enrich the sample is either by acquiring larger number of events or by using buffy coat because of neutropenia and monocytopenia [31, 37] .
The other technical issue that must be considered includes the panel of antibodies and gating strategy used for granulocytes and monocytes. Various initial studies were based on light scatter properties such FSC and SSC for gating of these cell types [35] [36] [37] [38] [39] . Our previous experience had demonstrated that in a panel of antibodies (CD55, CD59, CD24 and CD66b), the intensity of CD55 was better than CD59 on granulocytes. The combination of CD24 and CD66b has added advantage of clearly separating granulocytes population from the eosinophils. However significant problem arises in the setting of cytopenia(s) in AA and MDS [21] [22] [23] [24] [25] . Therefore, it is now recommended to use non-GPI linked specific lineage markers such as CD15 and CD33/CD64 for granulocytes and monocytes respectively, in addition to CD45 for initial gating strategy. The recent guidelines state that CD64 gives better results when compared to CD33 [31] . In our experience, both these markers are equally good in delineating monocyte population.
Sutherland et al. recommends that two GPI linked antigens are assessed to confirm PNH on two different lineages, most commonly on RBCs and granulocyte/monocyte series. This is because in rare hereditary disorders, absence of specific cell surface antigen causes negativity for that monoclonal antibody tested and in order to increase the sensitivity of the test, double negativity is recommended for two GPI-linked antigens [13] . Therefore in multicolour flowcytometry, in addition to the above markers, one should use CD14 and CD24 for monocytes and granulocytes respectively. The monocytes clone size is generally larger than neutrophils clone size and both correlate well with thrombotic risk [18, 23, [28] [29] [30] . Their clone size is almost always larger than RBC clone size because of hemolysis [31, 38, 39] .
In general, lymphocytes are not recommended for PNH testing because of their longer life span and only those lymphocytes originated after the onset of disease will be lacking in 'GPI-AP'. Therefore, in patients with recent onset of PNH, testing of lymphocytes will give rise to erroneous results [31] . The advantage with the lymphocytes is that it can be used as internal control of PNH testing [36, 37] .
Fluorescent Aerolysin (FLAER)
Aerolysin is the toxin secreted by bacterium Aeromonas hydrophilia. It is secreted as inactive form, pro-aerolysin, which upon proteolytic cleavage of C-terminal peptide becomes active form. It binds to the cell surface structures, oligomerizes and forms channels resulting in cell lysis [9, 13, 42] . In flow cytometry, mutant form of pro-aerolysin is tagged with fluorescent marker, usually FITC (Alexa Flour 488). This reagent requires activating proteases which is seen in all peripheral blood cells except red cells [14] [15] [16] .
Using FLAER, various studies could reliably diagnose PNH with high sensitivity and show comparable results with conventional flow cytometric immunophenotyping (FCMI) results, thereby allowing the identification of GPInegative granulocyte population as small as 0.5% [5, 15, 16, 29] . Since FLAER binds selectively to GPI anchor itself, Brodsky et al. [43] found that FLAER detected similar or higher proportion of PNH monocytes and granulocytes when compared to anti-CD59.
A single tube assay can be performed by combining FLAER with other monoclonal antibodies such as CD45, CD33, and CD14; thereby able to analyse FLAER and the GPI-linked marker CD14 on neutrophils and monocytes simultaneously [31] . In our experience using six color and two laser flow cytometry (BD FACS Canto II), similarly a single tube assay was performed with CD45, CD15, CD33, CD14, CD24 and FLAER (Figs. 1, 2) . We compared this single tube assay with two tube assay performed using CD55 and CD59 in one tube and CD16 and CD66b in another tube. Using FLAER based single tube assay, keeping receiver operator curve (ROC) cut-off of 0.7% for neutrophils and 0.9% for monocytes, we could pick up smaller clones of even \1% in four cases of AA and MDS which were otherwise not picked up on two tube assay. Similarly Sreedharanunni et al. [44] emphasised this approach of FLAER based flow cytometric testing to be useful in pediatric AA patients. The authors could demonstrate improved PNH clone detection compared to non-FLAER based screening techniques. Therefore in agreement with other study, FLAER combined with multiparameter flow cytometry offered an improved assay not only for diagnosis and monitoring of PNH clones, but also proved to be more economical [15] .
It is more robust technique in which the samples can be utilized up to 48 h for testing. Although its use is restricted only to leucocytes, it gives better delineation of type I, II and III cells, particularly if PNH is associated with AA and MDS [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Nevertheless in the era of complement blockade therapy like eculizumab, the routine analysis of RBC by CD59 cannot be completely replaced by FLAER. This is because after starting therapy with this drug, monitoring of red cells is required which show increase in clone size despite decrease in hemolysis [12, 45] .
CD157
CD157 is another GPI-linked structure expressed on both granulocytes and monocytes. In order to provide improved testing algorithm, Sutherland et al. studied whether CD157 could replace the CD24 and CD14 in four-color granulocyte and monocyte assays respectively. This new marker was highly correlated (R 2 [ 0.99) over a wide range of samples (0.06-99.8% clone size), had similar high level of sensitivity and low background level in the normal samples [46] . The ongoing study in our department with a panel comprised of CD45, CD15, CD64, CD157 and FLAER showed similar results and proved to be more economical (Fig. 3) . 
Analysis of Platelets
Up to 10% of the normal platelets, the expression of CD55 and CD59 might be completely absent and in remaining 90%, the expression is generally weak. Therefore, other than research setting, there is no clear recommendation for immunophenotypic analysis of platelets in PNH [37, 38] .
Ancillary Investigations
In hemolytic PNH, biomarkers of intravascular hemolysis such as indirect hyperbilirubinemia, decrease in serum haptoglobin, reticulocytosis, and increased serum lactate dehydrogenase (LDH) enzyme are usually additional findings [1] [2] [3] [4] [5] 31] . Patients may present with renal failure due to hemoglobinuria and centrifuged urine deposit should be stained with Prussian blue stain to look for hemosiderin pigment in the epithelial cells [1] [2] [3] [4] [5] . Apart from chronic myeloid leukemia, the other condition where leucocyte alkaline phosphatase (LAP) stain would benefit is PNH. Since this is a 'GPI-AP', LAP score is reduced in PNH. But this test is of historical importance only and not widely practised [8] . Finally in patients with unexplained cytopenia(s), bone marrow aspiration and trephine biopsy is required to rule out associated AA and MDS [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Measurement of D-dimer is very useful in the evaluation and management of thrombotic events associated with PNH [47] . PIGA mutation analysis is confirmatory, however technically difficult and not widely available, mostly done only in research setting [48] .
Whom to Test?
The various clinical indications for PNH testing according to the recent ICCS guidelines are highlighted in the Table 1 [31].
When to Test and How Frequently to Test for Follow-Up?
The ICCS guidelines recommend that once a diagnosis of PNH is made, the test should be repeated every 3-6 months initially and then annually thereafter. The basis behind this frequent monitoring is that since PNH is an acquired disease, the clone size varies over a period of time [31] . In approximately 20-50% of the cases over a 5-year period, the clone remains stable, whereas in other 10-15% of cases, the clone size either increases or decreases with time or eventually disappears altogether [49, 50] . This monitoring is essential because patients with very small clone size are followed with observation alone. On the contrary, in the era of eculizumab therapy, treatment should be started at the earliest possible moment to prevent the complications, if the clone size increases on follow-up [1-5, 45, 51] .
How to Test?
The ICCS guidelines have described routine analysis in clinical laboratories as detecting abnormal PNH clone of C1% and high sensitivity analysis, in which as few as 0.01% clones are detected. The number of events to be analysed for routine and higher sensitivity analysis are 5000-10,000 and at least 1,00,000 specific cell events respectively. The sensitivities in such analysis should be 1 and 0.01% respectively. High-sensitivity analysis is the preferred method for picking up PNH-sc [14, 17, 31] . The detection of any clone size is important in these scenarios, because this serves as a biomarker for high likelihood of response to immunosuppressive therapy [25] .
How Results Should be Reported?
Most of the hematopathologists are well aware of this entity. However there is lack of consensus in the testing strategy and reporting terminology. This was highlighted in the study conducted by United Kingdom National External Quality Assurance Schemes (UK NEQAS) [37] .
It is advisable not to use the terminology such as 'positive or negative for PNH'. It is good laboratory practice to state whether PNH clone is present or absent in the report. For red cells, it is recommended to provide type I, II and III clone size [31] . With respect to granulocytes, the clinical significance of type II cells is uncertain. However, type III cells [50% are associated with significant risk for thrombosis [18, [28] [29] [30] [31] . It is also recommended that at least two different cell lineages should be tested for confirmatory diagnosis [31] . When the laboratory is handling the followup samples, the report should include the previous clone size and should highlight any changes in clone size. Ideally good communication with treating oncologist/hematologist is required for better management strategy [32] .
Quality Control and Validation
It is always encouraged to analyse large number of samples from normal subjects before establishing the test in the laboratory. It is also recommended for the laboratory to establish their sensitivity for red cells and granulocytes/monocytes [31, 37] . Since this disease is a rare entity and commercial controls are costly, to be more economical, the practical way is to use other cells such as lymphocytes as internal control because of their longer life span [36] .
The laboratory should take part in external quality assurance program. Currently, there are two schemes available: (1) The College of American Pathologists scheme and (2) The United Kingdom National External Quality Assurance Scheme (UK NEQAS). The former assesses only red cell assay, whereas latter scheme is for leukocyte immunophenotyping [37] . Most of the laboratories faced significant problems in terms of both false positive and false negative test results which could have resulted in serious clinical consequences. In order to overcome these issues, recently ICCS has come up with guidelines for every aspect of testing strategy and uniform reporting format to be used throughout the world [31] . Since this condition is rare, it is recommended to exchange the samples between the laboratories [37] .
Conclusion
PNH is a life threatening disorder with various clinical manifestations. In this review, we have highlighted various techniques available with their basic principles, recent advances in diagnosis, advantages and their limitations. Currently the 'gold standard' test for making early diagnosis is flow cytometry with FLAER based testing [13] [14] [15] [16] . In order to overcome difficulties encountered in PNH testing as well as to have uniform reporting format throughout the world, ICCS has come up with recent guidelines that should be followed in our day to day practice [31] . Given the rarity of this disease with its protean manifestations, high index of suspicion is required to make early diagnosis to prevent complications and appropriate management [1-5, 45, 51] .
